Spinal and bulbar muscular atrophy (SBMA) is a neurodegenerative disease characterized by progressive loss of motor neurons in the spinal cord and/or bulbar region, resulting in muscle weakness and atrophy. These disorders are genetically determined and are mainly associated with inherited mutations that lead to dysfunction of motor neurons. The disease can manifest itself in different forms, each with its own characteristics and progression. Clinical manifestations include weakness in the limbs, difficulty swallowing and speaking, which significantly impairs the quality of life of patients. As the disease progresses, the rate of development and the complexity of treatment can depend on the disease.
History of the disease and interesting historical facts
The history of spinal and bulbar muscular atrophy research dates back to the 19th century, when cases of muscle weakness and atrophy associated with neuronal loss were first described. In 1869, French neurologist Jules Guihen, who first identified amyotrophic lateral sclerosis, described cases that later became known as bulbar amyotrophy. Later, in 1956, American neurologists John and Richard St. John conducted the first systematic studies on spinal muscular atrophy (SMA). Since then, a significant amount of data has been accumulated on the genetic mechanisms of this disease and its biomedical aspects. In 1995 and since 2016, when the first genetic therapy was developed, a new era of medical care has emerged, focused on the treatment and management of diseases associated with neuronal loss.
Epidemiology
Before talking about statistics, it is worth noting that spinal and bulbar muscular atrophy are rare diseases. According to various epidemiological studies, the prevalence of SBMA varies from 1 in 6,000 to 1 in 10,000 newborns. In Europe and North America, the incidence is higher than in other regions, probably due to higher diagnostic capabilities and genetic screening. In addition, men are considered to be much more susceptible to the disease than women, the ratio is approximately 1.5:1. It is noted that about 70% cases of SBMA are hereditary, which emphasizes the importance of genetic testing in high riesgo populations.
Genetic predisposition to this disease
Spinal and bulbar muscular atrophy is most often associated with mutations in the SMN1 (Survival Motor Neuron 1) gene. This gene is responsible for the synthesis of a protein necessary for the vital activity of motor neurons. The presence of duplications of the SMN2 gene, which practically does not encode a functional protein, is also important for the phenotype of the disease. Variations in the number of SMN2 copies can affect the severity of SBMA manifestations. Mutations in other genes, such as SHANK3, ASAH1, DYNC1H1 and others, can also cause secondary forms of spinal muscular atrophy, which are less common, but no less important for understanding the genetic mechanisms of the disease.
Risk factors for the development of this disease
A number of genetic and environmental factors may increase the risk of developing spinal and bulbar muscular atrophy. It is important to highlight the following risk factors:
- Hereditary predisposition (autosomal recessive inheritance);
- Family history of SBMA or other neurodegenerative diseases;
- Some viral infections are thought to trigger the disease development mechanism;
- Environmental factors such as toxin exposures (eg, pesticides) have been studied in the context of the pathogenesis of neurodegenerative diseases.
Diagnosis of this disease
Diagnosis of spinal and bulbar muscular atrophy includes several key stages:
- Main symptoms: The first signs may be muscle weakness, muscle atrophy, difficulty swallowing, speaking and breathing. It is important to take a complete medical history and assess the neurological status;
- Laboratory tests: Tests for levels of specific proteins, such as SMN protein, may help in making a diagnosis;
- Radiological examinations: MRI can be used to rule out other causes of muscle atrophy and to evaluate the condition of the spinal cord;
- Other types of diagnostics: electromyography (EMG) allows to evaluate the electrophysiological activity of muscles and motor neurons;
- Differential diagnosis: It is important to rule out other neurological diseases such as muscular dystrophy, amyotrophic lateral sclerosis, and hemiplegia.
Treatment
Treatment of spinal and bulbar muscular atrophy is multidisciplinary and includes the following approaches:
- General treatment: Rehabilitation interventions, including physical therapy and music therapy, can help improve quality of life;
- Pharmacological treatment: The first approved drugs, Sosinure Detemrologe and Elexodar (nusinersen), affect the level of SMN protein;
- Surgical treatment: In rare cases, surgery may be considered to correct complications such as spinal curvature;
- Other types of treatment: Supportive care may include the use of oxygen therapy and mechanical ventilation.
List of medications used to treat this disease
Among the main drugs used to treat spinal and bulbar muscular atrophy, the following can be distinguished:
- Nusinersen (Spinraza);
- Rizosert (Zolgensma – gene therapy);
- Edistar (Radicava) - to relieve symptoms;
- Some supportive medications to improve quality of life.
Disease monitoring
Long-term monitoring of the patient's condition with SBMA includes control stages and assessment of the condition:
- Regular neurological examinations to assess disease progression;
- Laboratory monitoring of SMN protein levels and other biomarkers;
- Dynamic monitoring of respiratory function and atrophy progression;
- Forecast: depending on the clinical variant of the disease, the prognosis may vary from a mild form to a severe disabling stage;
- Complications: Possible complications include respiratory infections, food aspiration, and loss of functional capacity.
Age-related features of the disease
Spinal and bulbar muscular atrophy can manifest at different ages and have different clinical manifestations:
- Childhood: in most cases, the disease manifests itself in early childhood, which leads to significant disturbances in motor functions;
- Adolescence: adolescents may develop milder forms of the disease with slow progression;
- Adulthood: In adults, more severe forms are most often diagnosed, manifesting with clear symptoms, including bulbar atrophy.
Questions and Answers
- What is spinal and bulbar muscular atrophy? It is a neurodegenerative disease associated with the loss of motor neurons, resulting in muscle weakness and atrophy.
- What is the genetic inheritance of the disease? Spinal and bulbar muscular atrophy is inherited in an autosomal recessive manner, most often associated with mutations in the SMN1 gene.
- What are the main psychosocial consequences for patients with SBMA? Patients often face limited physical activity, isolation and increasing dependence on others, which requires comprehensive rehabilitation.
- Is there a treatment for spinal and bulbar muscular atrophy? Yes, there are treatments such as nusinersen and gene therapy that improve quality of life and slow the progression of the disease.
- How is SBMA diagnosed? Diagnosis includes a special examination, electromyography, tests for SMN protein levels and MRI.
